PYREXIA and Diazepam

PatientsVille

Find and Compare Side Effects

PYREXIA Symptoms and Causes

A fever is a body temperature that is higher than normal. A normal temperature can vary from person to person, but it is usually around 98.6 F. A fever is not a disease. It is usually a sign that your body is trying to fight an illness or infection.

Infections cause most fevers. You get a fever because your body is trying to kill the virus or bacteria that caused the infection. Most of those bacteria and viruses do well when your body is at your normal temperature. But if you have a fever, it is harder for them to survive. Fever also activates your body's immune system.

Other causes of fevers include

Medicines, including some antibiotics, blood pressure medicines, and anti-seizure medicines

Heat illness

Cancers

Autoimmune diseases

Some childhood immunizations

Treatment depends on the cause of your fever. If the fever is very high, your health care provider may recommend taking an over-the-counter medicine such as acetaminophen or ibuprofen. Adults can also take aspirin, but children with fevers should not take aspirin. It is also important to drink enough liquids, to prevent dehydration.

PYREXIA Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.

To evaluate the life span and decay curve of effector CD8 T cells after immunization with 17D yellow fever vaccine; To evaluate the rate of homeostatic turnover of memory CD8 T cells after immunization with 17D yellow fever vaccine

Change in Immunogenicity; Percentage of subjects with symptoms following Q fever vaccination; Percentage of subjects with erythema following Q fever vaccination along with severity and association with vaccination; Percentage of subjects with induration following Q fever vaccination along with severity and association with vaccination; Percentage of subjects with each AE, system organ class of AE, severity, and association with vaccination; Percentage of subjects with symptoms following Q fever skin test antigen; Percentage of subjects with erythema following Q fever skin test antigen along with severity and association with skin test antigen; Percentage of subjects with induration following Q fever skin test antigen along with severity and association with skin test antigen; Percentage of subjects with each AE, system organ class of AE, severity, and association with skin test antigen

Proportion of patients with each disease among all febrile patients, overall and stratified by HIV status; Proportion of febrile patients with acute respiratory infection infected with a certain respiratory pathogen, compared to the proportion of healthy controls infected with the same pathogen.

To evaluate safety of hyperthermia and proton beam treatment in unresectable soft tissue sarcomas; To evaluate the local response to hyperthermia and proton beam therapy as a preoperative regimen for unresectable soft tissue sarcomaLocal control

The percentage of patients with failed treatment; All-cause mortality; Infection-related mortality; The length of hospitalization in days; Unexpected re-admission other than for planned chemotherapy or other elective treatment.; The recurrence of fever within 24 hours after discontinuation of antibiotic therapy.; The total number of febrile episodes during neutropenia; Time to defervescence; Antibiotic or antifungal treatment within 30days after discharge other than standard antibiotic prophylaxis.; Incidence and prevalence of Clostridium difficile infection; Incidence and prevalence of liver and kidney dysfunction; Candida spp. colonization in (surveillance) cultures; Cost of antimicrobial therapy per admission; MASCC-score; The percentage of patients with mucositis and positive blood cultures or short treatment failure.; Bacterial resistance in blood cultures and surveillance cultures (including minimal inhibitory concentrations (MIC)).

Evaluate the safety and tolerability of interstitial and endocavitary ultrasound hyperthermia therapy; Evaluate the feasibility, defined as being able to administer hyperthermia at a specified temperature range and thermal dose.; Characterize the interstitial and endocavitary ultrasound heating technology by describing the thermal parameters including attainable temperature and thermal dose distribution and duration at the tumor treatment region.

To determine the bioequivalence of ThermoDox when used with hyperthermia among patients with RCW breast cancer.; To determine efficacy of ThermoDox in combination with Hyperthermia; To evaluate the safety of ThermoDox in combination with Hyperthermia

Time to local tumor progression after combined hyperthermia and RT; Objective response rate of combined hyperthermia and RT; Change from baseline quality of life at 3 months; Local tumor progression free survival rate after combined hyperthermia and RT; Adverse event after combined hyperthermia and RT.; Overall survival rate after combined hyperthermia and RT

Maximal change in temperature during the 4-hour period after enrollment.; Proportion of patients with a drop of at least 1°C and 2°C in mean temperature at 4h. Decrement in fever at each time point, and the area under the temperature (versus time) curve. Proportion of patients with temperature < 38 at 4 hours.

If you think you may have a medical emergency, call your doctor or 911 immediately.

By accessing this website, you are indicating your acknowledgement and acceptance of these Terms of Use. These Terms of Use are subject to change by WinFirst LLC at any time in its discretion. Your use of WinFirst LLC Site after such changes are implemented constitutes your acknowledgement and acceptance of the changes. Please consult these Terms of Use regularly.
PatientsVille.com does not provide medical advice, diagnosis or treatment. The information contained on PatientsVille.com site has not been scientifically or otherwise verified as to a cause and effect relationship and cannot be used to estimate the incidence of adverse drug reactions or for establishing or changing of patient treatments.